Publications 2024

Egeland EV, Seip K, Skourti E, Øy GF, Pettersen SJ, Pandya AD, Dahle MA, Haugen MH, Kristian A, Nakken S, Engebraaten O, Mælandsmo GM, Prasmickaite L (2024)
The SRC-family serves as a therapeutic target in triple negative breast cancer with acquired resistance to chemotherapy
Br J Cancer, 131 (10), 1656-1667
DOI 10.1038/s41416-024-02875-5, PubMed 39390250

Valsalakumari R, Pandya AD, Prasmickaite L, Kvalvaag A, Myrann AG, Åslund AKO, Kjos MS, Fontecha-Cuenca C, Haroon HB, Ribeiro ARS, Horejs-Hoeck J, Moghimi SM, Mørch Ý, Skotland T, Sandvig K, Mælandsmo GM, Iversen TG (2024)
Preclinical Efficacy of Cabazitaxel Loaded Poly(2-alkyl cyanoacrylate) Nanoparticle Variants
Int J Nanomedicine, 19, 3009-3029
DOI 10.2147/IJN.S450283, PubMed 38562610

Publications 2023

Ghannoum S, Fantini D, Zahoor M, Reiterer V, Phuyal S, Leoncio Netto W, Sørensen Ø, Iyer A, Sengupta D, Prasmickaite L, Mælandsmo GM, Köhn-Luque A, Farhan H (2023)
A combined experimental-computational approach uncovers a role for the Golgi matrix protein Giantin in breast cancer progression
PLoS Comput Biol, 19 (4), e1010995
DOI 10.1371/journal.pcbi.1010995, PubMed 37068117

Haugen MH, von der Lippe Gythfeldt H, Egeland EV, Svartdal Normann L, Pandya AD, Vedin LL, Juell S, Tenstad E, Øy GF, Kristian A, Marangoni E, Sørlie T, Steffensen K, Maelandsmo GM, Engebraaten O (2023)
Liver X receptors induce antiproliferative effects in basal-like breast cancer
Mol Oncol, 17 (10), 2041-2055
DOI 10.1002/1878-0261.13476, PubMed 37341140

Knutsen E, Das Sajib S, Fiskaa T, Lorens J, Gudjonsson T, Mælandsmo GM, Johansen SD, Seternes OM, Perander M (2023)
Identification of a core EMT signature that separates basal-like breast cancers into partial- and post-EMT subtypes
Front Oncol, 13, 1249895
DOI 10.3389/fonc.2023.1249895, PubMed 38111531

Normann LS, Haugen MH, Hongisto V, Aure MR, Leivonen SK, Kristensen VN, Tahiri A, Engebraaten O, Sahlberg KK, Mælandsmo GM (2023)
High-throughput screen in vitro identifies dasatinib as a candidate for combinatorial treatment with HER2-targeting drugs in breast cancer
PLoS One, 18 (1), e0280507
DOI 10.1371/journal.pone.0280507, PubMed 36706086

Nunes-Xavier CE, Emaldi M, Mingo J, Øyjord T, Mælandsmo GM, Fodstad Ø, Errarte P, Larrinaga G, Llarena R, López JI, Pulido R (2023)
The expression pattern of pyruvate dehydrogenase kinases predicts prognosis and correlates with immune exhaustion in clear cell renal cell carcinoma
Sci Rep, 13 (1), 7339
DOI 10.1038/s41598-023-34087-x, PubMed 37147361

Nunes-Xavier CE, Emaldi M, Mingo J, Øyjord T, Mælandsmo GM, Fodstad Ø, Errarte P, Larrinaga G, Llarena R, López JI, Pulido R (2023)
Author Correction: The expression pattern of pyruvate dehydrogenase kinases predicts prognosis and correlates with immune exhaustion in clear cell renal cell carcinoma
Sci Rep, 13 (1), 9186
DOI 10.1038/s41598-023-36328-5, PubMed 37280349

Nygaard V, Ree AH, Dagenborg VJ, Børresen-Dale AL, Edwin B, Fretland ÅA, Grzyb K, Haugen MH, Mælandsmo GM, Flatmark K (2023)
A PRRX1 Signature Identifies TIM-3 and VISTA as Potential Immune Checkpoint Targets in a Subgroup of Microsatellite Stable Colorectal Cancer Liver Metastases
Cancer Res Commun, 3 (2), 235-244
DOI 10.1158/2767-9764.CRC-22-0295, PubMed 36968142

Pettersen S, Øy GF, Egeland EV, Juell S, Engebråten O, Mælandsmo GM, Prasmickaite L (2023)
Breast cancer patient-derived explant cultures recapitulate in vivo drug responses
Front Oncol, 13, 1040665
DOI 10.3389/fonc.2023.1040665, PubMed 36910663

Publications 2022

Ambrosini M, Del Re M, Manca P, Hendifar A, Drilon A, Harada G, Ree AH, Klempner S, Mælandsmo GM, Flatmark K, Russnes HG, Cleary JM, Singh H, Sottotetti E, Martinetti A, Randon G, Sartore-Bianchi A, Capone I, Milione M, Di Bartolomeo M, Pietrantonio F (2022)
ALK Inhibitors in Patients With ALK Fusion-Positive GI Cancers: An International Data Set and a Molecular Case Series
JCO Precis Oncol, 6 (1), e2200015
DOI 10.1200/PO.22.00015, PubMed 35476549

Fiorito E, Szybowska P, Haugsten EM, Kostas M, Øy GF, Wiedlocha A, Singh S, Nakken S, Mælandsmo GM, Fletcher JA, Meza-Zepeda LA, Wesche J (2022)
Strategies to inhibit FGFR4 V550L-driven rhabdomyosarcoma
Br J Cancer, 127 (11), 1939-1953
DOI 10.1038/s41416-022-01973-6, PubMed 36097178

Fusser M, Øverbye A, Pandya AD, Mørch Ý, Borgos SE, Kildal W, Snipstad S, Sulheim E, Fleten KG, Askautrud HA, Engebraaten O, Flatmark K, Iversen TG, Sandvig K, Skotland T, Mælandsmo GM (2022)
Corrigendum to "Cabazitaxel-loaded Poly(2-ethylbutyl cyanoacrylate) nanoparticles improve treatment efficacy in a patient derived breast cancer xenograft", [Journal of Control Release, 293 (2019) 183-192]
J Control Release, 349, 1
DOI 10.1016/j.jconrel.2022.06.040, PubMed 35792388

Normann LS, Haugen MH, Aure MR, Kristensen VN, Mælandsmo GM, Sahlberg KK (2022)
miR-101-5p Acts as a Tumor Suppressor in HER2-Positive Breast Cancer Cells and Improves Targeted Therapy
Breast Cancer (Dove Med Press), 14, 25-39
DOI 10.2147/BCTT.S338404, PubMed 35256859

Nunes-Xavier CE, Emaldi M, Guldvik IJ, Ramberg H, Taskén KA, Mælandsmo GM, Fodstad Ø, Llarena R, Pulido R, López JI (2022)
Correlation of expression of Major Vault Protein with androgen receptor and immune checkpoint protein B7-H3, and with poor prognosis in prostate cancer
Pathol Res Pract, 241, 154243
DOI 10.1016/j.prp.2022.154243, PubMed 36481650

Nunes-Xavier CE, Mingo J, Emaldi M, Flem-Karlsen K, Mælandsmo GM, Fodstad Ø, Llarena R, López JI, Pulido R (2022)
Heterogeneous Expression and Subcellular Localization of Pyruvate Dehydrogenase Complex in Prostate Cancer
Front Oncol, 12, 873516
DOI 10.3389/fonc.2022.873516, PubMed 35692804

Nyakas M, Fleten KG, Haugen MH, Engedal N, Sveen C, Farstad IN, Flørenes VA, Prasmickaite L, Mælandsmo GM, Seip K (2022)
AXL inhibition improves BRAF-targeted treatment in melanoma
Sci Rep, 12 (1), 5076
DOI 10.1038/s41598-022-09078-z, PubMed 35332208

Ree AH, Mælandsmo GM, Flatmark K, Russnes HG, Gómez Castañeda M, Aas E (2022)
Cost-effectiveness of molecularly matched off-label therapies for end-stage cancer - the MetAction precision medicine study
Acta Oncol, 61 (8), 955-962
DOI 10.1080/0284186X.2022.2098053, PubMed 35943168

Tellez-Gabriel M, Tekpli X, Reine TM, Hegge B, Nielsen SR, Chen M, Moi L, Normann LS, Busund LR, Calin GA, Mælandsmo GM, Perander M, Theocharis AD, Kolset SO, Knutsen E (2022)
Serglycin Is Involved in TGF-β Induced Epithelial-Mesenchymal Transition and Is Highly Expressed by Immune Cells in Breast Cancer Tissue
Front Oncol, 12, 868868
DOI 10.3389/fonc.2022.868868, PubMed 35494005

Publications 2021

Barkovskaya A, Goodwin CM, Seip K, Hilmarsdottir B, Pettersen S, Stalnecker C, Engebraaten O, Briem E, Der CJ, Moestue SA, Gudjonsson T, Maelandsmo GM, Prasmickaite L (2021)
Detection of phenotype-specific therapeutic vulnerabilities in breast cells using a CRISPR loss-of-function screen
Mol Oncol, 15 (8), 2026-2045
DOI 10.1002/1878-0261.12951, PubMed 33759347

Dagenborg VJ, Marshall SE, Grzyb K, Fretland ÅA, Lund-Iversen M, Mælandsmo GM, Ree AH, Edwin B, Yaqub S, Flatmark K (2021)
Low Concordance Between T-Cell Densities in Matched Primary Tumors and Liver Metastases in Microsatellite Stable Colorectal Cancer
Front Oncol, 11, 671629
DOI 10.3389/fonc.2021.671629, PubMed 34178659

Fleten KG, Eksteen JJ, Mauseth B, Camilio KA, Vasskog T, Sveinbjørnsson B, Rekdal Ø, Mælandsmo GM, Flatmark K (2021)
Oncolytic peptides DTT-205 and DTT-304 induce complete regression and protective immune response in experimental murine colorectal cancer
Sci Rep, 11 (1), 6731
DOI 10.1038/s41598-021-86239-6, PubMed 33762676

Haugen MH, Lingjærde OC, Hedenfalk I, Garred Ø, Borgen E, Loman N, Hatschek T, Børresen-Dale AL, Naume B, Mills GB, Mælandsmo GM, Engebraaten O (2021)
Protein Signature Predicts Response to Neoadjuvant Treatment With Chemotherapy and Bevacizumab in HER2-Negative Breast Cancers
JCO Precis Oncol, 5
DOI 10.1200/PO.20.00086, PubMed 34036235

Karvelsson ST, Sigurdsson A, Seip K, Grinde MT, Wang Q, Johannsson F, Mælandsmo GM, Moestue SA, Rolfsson O, Halldorsson S (2021)
EMT-Derived Alterations in Glutamine Metabolism Sensitize Mesenchymal Breast Cells to mTOR Inhibition
Mol Cancer Res, 19 (9), 1546-1558
DOI 10.1158/1541-7786.MCR-20-0962, PubMed 34088869

Karvelsson ST, Wang Q, Hilmarsdottir B, Sigurdsson A, Moestue SA, Mælandsmo GM, Halldorsson S, Gudmundsson S, Rolfsson O (2021)
Argininosuccinate lyase is a metabolic vulnerability in breast development and cancer
NPJ Syst Biol Appl, 7 (1), 36
DOI 10.1038/s41540-021-00195-5, PubMed 34535676

Krzyscik MA, Zakrzewska M, Sørensen V, Øy GF, Brunheim S, Haugsten EM, Mælandsmo GM, Wiedlocha A, Otlewski J (2021)
Fibroblast Growth Factor 2 Conjugated with Monomethyl Auristatin E Inhibits Tumor Growth in a Mouse Model
Biomacromolecules, 22 (10), 4169-4180
DOI 10.1021/acs.biomac.1c00662, PubMed 34542998

Normann LS, Aure MR, Leivonen SK, Haugen MH, Hongisto V, Kristensen VN, Mælandsmo GM, Sahlberg KK (2021)
MicroRNA in combination with HER2-targeting drugs reduces breast cancer cell viability in vitro
Sci Rep, 11 (1), 10893
DOI 10.1038/s41598-021-90385-2, PubMed 34035375

Nunes-Xavier CE, Kildal W, Kleppe A, Danielsen HE, Waehre H, Llarena R, Maelandsmo GM, Fodstad Ø, Pulido R, López JI (2021)
Immune checkpoint B7-H3 protein expression is associated with poor outcome and androgen receptor status in prostate cancer
Prostate, 81 (12), 838-848
DOI 10.1002/pros.24180, PubMed 34125445

Pandya AD, Iversen TG, Moestue S, Grinde MT, Mørch Ý, Snipstad S, Åslund AKO, Øy GF, Kildal W, Engebråten O, Sandvig K, Skotland T, Mælandsmo GM (2021)
Biodistribution of Poly(alkyl cyanoacrylate) Nanoparticles in Mice and Effect on Tumor Infiltration of Macrophages into a Patient-Derived Breast Cancer Xenograft
Nanomaterials (Basel), 11 (5)
DOI 10.3390/nano11051140, PubMed 33924869

Svendsen HA, Meling TR, Nygaard V, Waagene S, Russnes H, Juell S, Rogne SG, Pahnke J, Helseth E, Fodstad Ø, Maelandsmo GM (2021)
Novel human melanoma brain metastasis models in athymic nude fox1^nu mice: Site-specific metastasis patterns reflecting their clinical origin
Cancer Med, 10 (23), 8604-8613
DOI 10.1002/cam4.4334, PubMed 34612023

Tamhane T, Njenga RW, Burden RE, Bueth H, Maelandsmo GM, Haugen MH, Scott CJ, Brix K (2021)
Trafficking of Full-Length and N-Terminally Truncated Cathepsin B in Human Colorectal Carcinoma Cells
Appl. Sci.-Basel, 11 (24), 11936
DOI 10.3390/app112411936

Valsalakumari R, Yadava SK, Szwed M, Pandya AD, Mælandsmo GM, Torgersen ML, Iversen TG, Skotland T, Sandvig K, Giri J (2021)
Mechanism of cellular uptake and cytotoxicity of paclitaxel loaded lipid nanocapsules in breast cancer cells
Int J Pharm, 597, 120217
DOI 10.1016/j.ijpharm.2021.120217, PubMed 33486035

Publications 2020

Dillard P, Köksal H, Maggadottir SM, Winge-Main A, Pollmann S, Menard M, Myhre MR, Mælandsmo GM, Flørenes VA, Gaudernack G, Kvalheim G, Wälchli S, Inderberg EM (2020)
Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy
Mol Ther, 29 (3), 1199-1213
DOI 10.1016/j.ymthe.2020.11.019, PubMed 33212301

Flem-Karlsen K, Nyakas M, Farstad IN, McFadden E, Wernhoff P, Jacobsen KD, Flørenes VA, Mælandsmo GM (2020)
Soluble AXL as a marker of disease progression and survival in melanoma
PLoS One, 15 (1), e0227187
DOI 10.1371/journal.pone.0227187, PubMed 31917795

Halvorsen AR, Haugen MH, Öjlert ÅK, Lund-Iversen M, Jørgensen L, Solberg S, Mælandsmo GM, Brustugun OT, Helland Å (2020)
Protein Kinase C Isozymes Associated With Relapse Free Survival in Non-Small Cell Lung Cancer Patients
Front Oncol, 10, 590755
DOI 10.3389/fonc.2020.590755, PubMed 33324562

Knutsen E, Lellahi SM, Aure MR, Nord S, Fismen S, Larsen KB, Gabriel MT, Hedberg A, Bjørklund SS, Oslo Breast Cancer Research Consortium (OSBREAC), Bofin AM, Mælandsmo GM, Sørlie T, Mortensen ES, Perander M (2020)
The expression of the long NEAT1_2 isoform is associated with human epidermal growth factor receptor 2-positive breast cancers
Sci Rep, 10 (1), 1277
DOI 10.1038/s41598-020-57759-4, PubMed 31992741

Pandya AD, Øverbye A, Sahariah P, Gaware VS, Høgset H, Masson M, Høgset A, Mælandsmo GM, Skotland T, Sandvig K, Iversen TG (2020)
Drug-Loaded Photosensitizer-Chitosan Nanoparticles for Combinatorial Chemo- and Photodynamic-Therapy of Cancer
Biomacromolecules, 21 (4), 1489-1498
DOI 10.1021/acs.biomac.0c00061, PubMed 32092254

Ree AH, Nygaard V, Boye K, Heinrich D, Dueland S, Bergheim IR, Johansen C, Beiske K, Negård A, Lund-Iversen M, Nygaard V, Hovig E, Nakken S, Nasser S, Julsrud L, Reisse CH, Ruud EA, Kristensen VN, Flørenes VA, Geitvik GA, Lingjærde OC, Børresen-Dale AL, Russnes HG, Mælandsmo GM, Flatmark K (2020)
Molecularly matched therapy in the context of sensitivity, resistance, and safety; patient outcomes in end-stage cancer - the MetAction study
Acta Oncol, 59 (7), 733-740
DOI 10.1080/0284186X.2020.1742377, PubMed 32208873

Steinhaeuser SS, Morera E, Budkova Z, Schepsky A, Wang Q, Rolfsson O, Riedel A, Krueger A, Hilmarsdottir B, Maelandsmo GM, Valdimarsdottir B, Sigurdardottir AK, Agnarsson BA, Jonasson JG, Ingthorsson S, Traustadottir GA, Oskarsson T, Gudjonsson T (2020)
ECM1 secreted by HER2-overexpressing breast cancer cells promotes formation of a vascular niche accelerating cancer cell migration and invasion
Lab Invest, 100 (7), 928-944
DOI 10.1038/s41374-020-0415-6, PubMed 32203150

Torgersen ML, Judge PJ, Bada Juarez JF, Pandya AD, Fusser M, Davies CW, Maciejewska MK, Yin DJ, Maelandsmo GM, Skotland T, Watts A, Sandvig K (2020)
Physicochemical Characterization, Toxicity and In Vivo Biodistribution Studies of a Discoidal, Lipid-Based Drug Delivery Vehicle: Lipodisq Nanoparticles Containing Doxorubicin
J Biomed Nanotechnol, 16 (4), 419-431
DOI 10.1166/jbn.2020.2911, PubMed 32970975

Publications 2019

Barkovskaya A, Seip K, Hilmarsdottir B, Maelandsmo GM, Moestue SA, Itkonen HM (2019)
O-GlcNAc Transferase Inhibition Differentially Affects Breast Cancer Subtypes
Sci Rep, 9 (1), 5670
DOI 10.1038/s41598-019-42153-6, PubMed 30952976

Camilio KA, Wang MY, Mauseth B, Waagene S, Kvalheim G, Rekdal Ø, Sveinbjørnsson B, Mælandsmo GM (2019)
Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model
Breast Cancer Res, 21 (1), 9
DOI 10.1186/s13058-018-1092-x, PubMed 30670061

Flem-Karlsen K, McFadden E, Omar N, Haugen MH, Øy GF, Ryder T, Gullestad HP, Hermann R, Mælandsmo GM, Flørenes VA (2019)
Targeting AXL and the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Melanoma
Mol Cancer Ther, 19 (3), 895-905
DOI 10.1158/1535-7163.MCT-19-0290, PubMed 31871265

Flem-Karlsen K, Tekle C, Øyjord T, Flørenes VA, Mælandsmo GM, Fodstad Ø, Nunes-Xavier CE (2019)
p38 MAPK activation through B7-H3-mediated DUSP10 repression promotes chemoresistance
Sci Rep, 9 (1), 5839
DOI 10.1038/s41598-019-42303-w, PubMed 30967582

Flørenes VA, Flem-Karlsen K, McFadden E, Bergheim IR, Nygaard V, Nygård V, Farstad IN, Øy GF, Emilsen E, Giller-Fleten K, Ree AH, Flatmark K, Gullestad HP, Hermann R, Ryder T, Wernhoff P, Mælandsmo GM (2019)
A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases
Transl Oncol, 12 (7), 951-958
DOI 10.1016/j.tranon.2019.04.001, PubMed 31096111

Grinde MT, Hilmarsdottir B, Tunset HM, Henriksen IM, Kim J, Haugen MH, Rye MB, Mælandsmo GM, Moestue SA (2019)
Glutamine to proline conversion is associated with response to glutaminase inhibition in breast cancer
Breast Cancer Res, 21 (1), 61
DOI 10.1186/s13058-019-1141-0, PubMed 31088535

Lien VT, Pettersen S, Haugen MH, Olberg DE, Maelandsmo GM, Klaveness J (2019)
Design, synthesis and biological evaluation of 6-substituted quinolines derived from cabozantinib as c-Met inhibitors
Arch Pharm (Weinheim), 352 (9), e1900101
DOI 10.1002/ardp.201900101, PubMed 31414521

Nome ME, Euceda LR, Jabeen S, Debik J, Bathen TF, Giskeødegård GF, Taskén KA, Maelandsmo GM, Halvorsen B, Yndestad A, Borgen E, Garred Ø, Aukrust P, Ueland T, Engebraaten O, Kristensen VN, Tekpli X (2019)
Serum levels of inflammation-related markers and metabolites predict response to neoadjuvant chemotherapy with and without bevacizumab in breast cancers
Int J Cancer, 146 (1), 223-235
DOI 10.1002/ijc.32638, PubMed 31444972

Nyakas M, Aamdal E, Jacobsen KD, Guren TK, Aamdal S, Hagene KT, Brunsvig P, Yndestad A, Halvorsen B, Tasken KA, Aukrust P, Maelandsmo GM, Ueland T (2019)
Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma
Clin Exp Immunol, 197 (1), 74-82
DOI 10.1111/cei.13283, PubMed 30821848

Pandya AD, Jäger E, Bagheri Fam S, Höcherl A, Jäger A, Sincari V, Nyström B, Štěpánek P, Skotland T, Sandvig K, Hrubý M, Mælandsmo GM (2019)
Paclitaxel-loaded biodegradable ROS-sensitive nanoparticles for cancer therapy
Int J Nanomedicine, 14, 6269-6285
DOI 10.2147/IJN.S208938, PubMed 31496685

Ree AH, Nygaard V, Russnes HG, Heinrich D, Nygaard V, Johansen C, Bergheim IR, Hovig E, Beiske K, Negård A, Børresen-Dale AL, Flatmark K, Mælandsmo GM (2019)
Responsiveness to PD-1 Blockade in End-Stage Colon Cancer with Gene Locus 9p24.1 Copy-Number Gain
Cancer Immunol Res, 7 (5), 701-706
DOI 10.1158/2326-6066.CIR-18-0777, PubMed 30804006

Saeednejad Zanjani L, Madjd Z, Rasti A, Asgari M, Abolhasani M, Tam KJ, Roudi R, Mælandsmo GM, Fodstad Ø, Andersson Y (2019)
Spheroid-Derived Cells From Renal Adenocarcinoma Have Low Telomerase Activity and High Stem-Like and Invasive Characteristics
Front Oncol, 9, 1302
DOI 10.3389/fonc.2019.01302, PubMed 31921617

Publications 2018

Berg J, Halvorsen AR, Bengtson MB, Taskén KA, Mælandsmo GM, Yndestad A, Halvorsen B, Brustugun OT, Aukrust P, Ueland T, Helland Å (2018)
Levels and prognostic impact of circulating markers of inflammation, endothelial activation and extracellular matrix remodelling in patients with lung cancer and chronic obstructive pulmonary disease
BMC Cancer, 18 (1), 739
DOI 10.1186/s12885-018-4659-0, PubMed 30005623

Eng MS, Kaur J, Prasmickaite L, Engesæter BØ, Weyergang A, Skarpen E, Berg K, Rosenblum MG, Mælandsmo GM, Høgset A, Ferrone S, Selbo PK (2018)
Enhanced targeting of triple-negative breast carcinoma and malignant melanoma by photochemical internalization of CSPG4-targeting immunotoxins
Photochem Photobiol Sci, 17 (5), 539-551
DOI 10.1039/C7PP00358G, PubMed 29565434

Fusser M, Øverbye A, Pandya AD, Mørch Ý, Borgos SE, Kildal W, Snipstad S, Sulheim E, Fleten KG, Askautrud HA, Engebraaten O, Flatmark K, Iversen TG, Sandvig K, Skotland T, Mælandsmo GM (2018)
Cabazitaxel-loaded Poly(2-ethylbutyl cyanoacrylate) nanoparticles improve treatment efficacy in a patient derived breast cancer xenograft
J Control Release, 293, 183-192
DOI 10.1016/j.jconrel.2018.11.029, PubMed 30529259

Prasmickaite L, Tenstad EM, Pettersen S, Jabeen S, Egeland EV, Nord S, Pandya A, Haugen MH, Kristensen VN, Børresen-Dale AL, Oslo Breast Cancer Research Consortium (OSBREAC), Engebråten O, Maelandsmo GM (2018)
Basal-like breast cancer engages tumor-supportive macrophages via secreted factors induced by extracellular S100A4
Mol Oncol, 12 (9), 1540-1558
DOI 10.1002/1878-0261.12319, PubMed 29741811

Seip K, Jørgensen K, Haselager MV, Albrecht M, Haugen MH, Egeland EV, Lucarelli P, Engebraaten O, Sauter T, Mælandsmo GM, Prasmickaite L (2018)
Stroma-induced phenotypic plasticity offers phenotype-specific targeting to improve melanoma treatment
Cancer Lett, 439, 1-13
DOI 10.1016/j.canlet.2018.09.023, PubMed 30240588

Publications 2017

Aure MR, Vitelli V, Jernström S, Kumar S, Krohn M, Due EU, Haukaas TH, Leivonen SK, Vollan HK, Lüders T, Rødland E, Vaske CJ, Zhao W, Møller EK, Nord S, Giskeødegård GF, Bathen TF, Caldas C, Tramm T, Alsner J, Overgaard J, Geisler J, Bukholm IR, Naume B, Schlichting E et al. (2017)
Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome
Breast Cancer Res, 19 (1), 44
DOI 10.1186/s13058-017-0812-y, PubMed 28356166

Byrne AT, Alférez DG, Amant F, Annibali D, Arribas J, Biankin AV, Bruna A, Budinská E, Caldas C, Chang DK, Clarke RB, Clevers H, Coukos G, Dangles-Marie V, Eckhardt SG, Gonzalez-Suarez E, Hermans E, Hidalgo M, Jarzabek MA, de Jong S, Jonkers J, Kemper K, Lanfrancone L, Mælandsmo GM, Marangoni E et al. (2017)
Interrogating open issues in cancer precision medicine with patient-derived xenografts
Nat Rev Cancer, 17 (4), 254-268
DOI 10.1038/nrc.2016.140, PubMed 28104906

Byrne AT, Alférez DG, Amant F, Annibali D, Arribas J, Biankin AV, Bruna A, Budinská E, Caldas C, Chang DK, Clarke RB, Clevers H, Coukos G, Dangles-Marie V, Eckhardt SG, Gonzalez-Suarez E, Hermans E, Hidalgo M, Jarzabek MA, de Jong S, Jonkers J, Kemper K, Lanfrancone L, Mælandsmo GM, Marangoni E et al. (2017)
Interrogating open issues in cancer medicine with patient-derived xenografts
Nat Rev Cancer, 17 (10), 632 (in press)
DOI 10.1038/nrc.2017.85, PubMed 28912576

Egeland EV, Boye K, Park D, Synnestvedt M, Sauer T, Oslo Breast Cancer Consortium (OSBREAC), Naume B, Borgen E, Mælandsmo GM (2017)
Prognostic significance of S100A4-expression and subcellular localization in early-stage breast cancer
Breast Cancer Res Treat, 162 (1), 127-137
DOI 10.1007/s10549-016-4096-1, PubMed 28058579

Halldorsson S, Rohatgi N, Magnusdottir M, Choudhary KS, Gudjonsson T, Knutsen E, Barkovskaya A, Hilmarsdottir B, Perander M, Mælandsmo GM, Gudmundsson S, Rolfsson Ó (2017)
Metabolic re-wiring of isogenic breast epithelial cell lines following epithelial to mesenchymal transition
Cancer Lett, 396, 117-129
DOI 10.1016/j.canlet.2017.03.019, PubMed 28323032

Hilmarsdottir B, Briem E, Halldorsson S, Kricker J, Ingthorsson S, Gustafsdottir S, Mælandsmo GM, Magnusson MK, Gudjonsson T (2017)
Inhibition of PTP1B disrupts cell-cell adhesion and induces anoikis in breast epithelial cells
Cell Death Dis, 8 (5), e2769
DOI 10.1038/cddis.2017.177, PubMed 28492548

Jernström S, Hongisto V, Leivonen SK, Due EU, Tadele DS, Edgren H, Kallioniemi O, Perälä M, Mælandsmo GM, Sahlberg KK (2017)
Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment response
Breast Cancer (Dove Med Press), 9, 185-198
DOI 10.2147/BCTT.S115600, PubMed 28356768

Kristian A, Holtedahl JE, Torheim T, Futsaether C, Hernes E, Engebraaten O, Mælandsmo GM, Malinen E (2017)
Dynamic 2-Deoxy-2-[¹⁸F]Fluoro-D-Glucose Positron Emission Tomography for Chemotherapy Response Monitoring of Breast Cancer Xenografts
Mol Imaging Biol, 19 (2), 271-279
DOI 10.1007/s11307-016-0998-x, PubMed 27541026

Ree AH, Russnes HG, Heinrich D, Dueland S, Boye K, Nygaard V, Silwal-Pandit L, Østrup O, Hovig E, Nygaard V, Rødland EA, Nakken S, Øien JT, Johansen C, Bergheim IR, Skarpeteig V, Sathermugathevan M, Sauer T, Lund-Iversen M, Beiske K, Nasser S, Julsrud L, Reisse CH, Ruud EA, Flørenes VA et al. (2017)
Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate
ESMO Open, 2 (2), e000158
DOI 10.1136/esmoopen-2017-000158, PubMed 28761742

Østrup O, Dagenborg VJ, Rødland EA, Skarpeteig V, Silwal-Pandit L, Grzyb K, Berstad AE, Fretland ÅA, Mælandsmo GM, Børresen-Dale AL, Ree AH, Edwin B, Nygaard V, Flatmark K (2017)
Molecular signatures reflecting microenvironmental metabolism and chemotherapy-induced immunogenic cell death in colorectal liver metastases
Oncotarget, 8 (44), 76290-76304
DOI 10.18632/oncotarget.19350, PubMed 29100312

Øverbye A, Holsæter AM, Markus F, Škalko-Basnet N, Iversen TG, Torgersen ML, Sønstevold T, Engebraaten O, Flatmark K, Mælandsmo GM, Skotland T, Sandvig K (2017)
Ceramide-containing liposomes with doxorubicin: time and cell-dependent effect of C6 and C12 ceramide
Oncotarget, 8 (44), 76921-76934
DOI 10.18632/oncotarget.20217, PubMed 29100358

Publications 2016

Boye K, Jacob H, Frikstad KA, Nesland JM, Maelandsmo GM, Dahl O, Nesbakken A, Flatmark K (2016)
Prognostic significance of S100A4 expression in stage II and III colorectal cancer: results from a population-based series and a randomized phase III study on adjuvant chemotherapy
Cancer Med, 5 (8), 1840-9
DOI 10.1002/cam4.766, PubMed 27273130

Braadland PR, Grytli HH, Ramberg H, Katz B, Kellman R, Gauthier-Landry L, Fazli L, Krobert KA, Wang W, Levy FO, Bjartell A, Berge V, Rennie PS, Mellgren G, Mælandsmo GM, Svindland A, Barbier O, Taskén KA (2016)
Low β₂-adrenergic receptor level may promote development of castration resistant prostate cancer and altered steroid metabolism
Oncotarget, 7 (2), 1878-94
DOI 10.18632/oncotarget.6479, PubMed 26646591

Egeland EV, Flatmark K, Nesland JM, Flørenes VA, Mælandsmo GM, Boye K (2016)
Expression and clinical significance of Wee1 in colorectal cancer
Tumour Biol, 37 (9), 12133-12140
DOI 10.1007/s13277-016-5081-3, PubMed 27220319

Evensen L, Johansen PL, Koster G, Zhu K, Herfindal L, Speth M, Fenaroli F, Hildahl J, Bagherifam S, Tulotta C, Prasmickaite L, Mælandsmo GM, Snaar-Jagalska E, Griffiths G (2016)
Zebrafish as a model system for characterization of nanoparticles against cancer
Nanoscale, 8 (2), 862-77
DOI 10.1039/c5nr07289a, PubMed 26648525

Fleten KG, Bakke KM, Mælandsmo GM, Abildgaard A, Redalen KR, Flatmark K (2016)
Use of non-invasive imaging to monitor response to aflibercept treatment in murine models of colorectal cancer liver metastases
Clin Exp Metastasis, 34 (1), 51-62
DOI 10.1007/s10585-016-9829-3, PubMed 27812769

Fleten KG, Flørenes VA, Prasmickaite L, Hill O, Sykora J, Mælandsmo GM, Engesæter B (2016)
hvTRA, a novel TRAIL receptor agonist, induces apoptosis and sustained growth retardation in melanoma
Cell Death Discov, 2, 16081
DOI 10.1038/cddiscovery.2016.81, PubMed 28028438

Kim E, Kim J, Maelandsmo GM, Johansen B, Moestue SA (2016)
Anti-angiogenic therapy affects the relationship between tumor vascular structure and function: A correlation study between micro-computed tomography angiography and dynamic contrast enhanced MRI
Magn Reson Med, 78 (4), 1513-1522
DOI 10.1002/mrm.26547, PubMed 27888545

Kim E, Tunset HM, Cebulla J, Vettukattil R, Helgesen H, Feuerherm AJ, Engebråten O, Mælandsmo GM, Johansen B, Moestue SA (2016)
Anti-vascular effects of the cytosolic phospholipase A2 inhibitor AVX235 in a patient-derived basal-like breast cancer model
BMC Cancer, 16, 191
DOI 10.1186/s12885-016-2225-1, PubMed 26951085

Kongsgaard A, Boye K, Fodstad Ø, Juell S, Jørgensen LH, Solberg S, Helland Å, Brustugun OT, Mælandsmo GM (2016)
Detection of disseminated tumor cells in lymph nodes from patients with early stage non-small cell lung cancer
Diagn Pathol, 11 (1), 50
DOI 10.1186/s13000-016-0504-4, PubMed 27316334

Lindstad T, Qu S, Sikkeland J, Jin Y, Kristian A, Mælandsmo GM, Collas P, Saatcioglu F (2016)
STAMP2 is required for human adipose-derived stem cell differentiation and adipocyte-facilitated prostate cancer growth in vivo
Oncotarget, 8 (54), 91817-91827
DOI 10.18632/oncotarget.11131, PubMed 29190878

Seip K, Fleten KG, Barkovskaya A, Nygaard V, Haugen MH, Engesæter BØ, Mælandsmo GM, Prasmickaite L (2016)
Fibroblast-induced switching to the mesenchymal-like phenotype and PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors
Oncotarget, 7 (15), 19997-20015
DOI 10.18632/oncotarget.7671, PubMed 26918352

Westrøm S, Bønsdorff TB, Abbas N, Bruland ØS, Jonasdottir TJ, Mælandsmo GM, Larsen RH (2016)
Evaluation of CD146 as Target for Radioimmunotherapy against Osteosarcoma
PLoS One, 11 (10), e0165382
DOI 10.1371/journal.pone.0165382, PubMed 27776176

Publications 2015

Bettum IJ, Gorad SS, Barkovskaya A, Pettersen S, Moestue SA, Vasiliauskaite K, Tenstad E, Øyjord T, Risa Ø, Nygaard V, Mælandsmo GM, Prasmickaite L (2015)
Metabolic reprogramming supports the invasive phenotype in malignant melanoma
Cancer Lett, 366 (1), 71-83
DOI 10.1016/j.canlet.2015.06.006, PubMed 26095603

Egeland EV, Boye K, Pettersen SJ, Haugen MH, Øyjord T, Malerød L, Flatmark K, Mælandsmo GM (2015)
Enrichment of nuclear S100A4 during G2/M in colorectal cancer cells: possible association with cyclin B1 and centrosomes
Clin Exp Metastasis, 32 (8), 755-67
DOI 10.1007/s10585-015-9742-1, PubMed 26349943

Ingthorsson S, Andersen K, Hilmarsdottir B, Maelandsmo GM, Magnusson MK, Gudjonsson T (2015)
HER2 induced EMT and tumorigenicity in breast epithelial progenitor cells is inhibited by coexpression of EGFR
Oncogene, 35 (32), 4244-55
DOI 10.1038/onc.2015.489, PubMed 26686087

Jin Y, Wang L, Qu S, Sheng X, Kristian A, Mælandsmo GM, Pällmann N, Yuca E, Tekedereli I, Gorgulu K, Alpay N, Sood A, Lopez-Berestein G, Fazli L, Rennie P, Risberg B, Wæhre H, Danielsen HE, Ozpolat B, Saatcioglu F (2015)
STAMP2 increases oxidative stress and is critical for prostate cancer
EMBO Mol Med, 7 (3), 315-31
DOI 10.15252/emmm.201404181, PubMed 25680860

Prasmickaite L, Berge G, Bettum IJ, Aamdal S, Hansson J, Bastholt L, Øijordsbakken M, Boye K, Mælandsmo GM (2015)
Evaluation of serum osteopontin level and gene polymorphism as biomarkers: analyses from the Nordic Adjuvant Interferon alpha Melanoma trial
Cancer Immunol Immunother, 64 (6), 769-76
DOI 10.1007/s00262-015-1686-4, PubMed 25832001

Skrbo N, Tenstad E, Mælandsmo GM, Sørlie T, Andersen K (2015)
From autonomy to community; new perspectives on tumorigenicity and therapy resistance
Cancer Treat Rev, 41 (10), 809-13
DOI 10.1016/j.ctrv.2015.10.004, PubMed 26519005

Tamhane T, Lllukkumbura R, Lu S, Maelandsmo GM, Haugen MH, Brix K (2015)
Nuclear cathepsin L activity is required for cell cycle progression of colorectal carcinoma cells
Biochimie, 122, 208-18
DOI 10.1016/j.biochi.2015.09.003, PubMed 26343556

Tamhane T, Wolters BK, Illukkumbura R, Maelandsmo GM, Haugen MH, Brix K (2015)
Construction of a plasmid coding for green fluorescent protein tagged cathepsin L and data on expression in colorectal carcinoma cells
Data Brief, 5, 468-75
DOI 10.1016/j.dib.2015.09.022, PubMed 26594658

Publications 2014

Bagherifam S, Griffiths GW, Mælandsmo GM, Nyström B, Hasirci V, Hasirci N (2014)
Poly(sebacic anhydride) nanocapsules as carriers: effects of preparation parameters on properties and release of doxorubicin
J Microencapsul, 32 (2), 166-74
DOI 10.3109/02652048.2014.973073, PubMed 25323326

Bagherifam S, Skjeldal FM, Griffiths G, Mælandsmo GM, Engebråten O, Nyström B, Hasirci V, Hasirci N (2014)
pH-responsive nano carriers for doxorubicin delivery
Pharm Res, 32 (4), 1249-63
DOI 10.1007/s11095-014-1530-0, PubMed 25288014

Esmaeili M, Moestue SA, Hamans BC, Veltien A, Kristian A, Engebråten O, Maelandsmo GM, Gribbestad IS, Bathen TF, Heerschap A (2014)
In vivo ³¹P magnetic resonance spectroscopic imaging (MRSI) for metabolic profiling of human breast cancer xenografts
J Magn Reson Imaging, 41 (3), 601-9
DOI 10.1002/jmri.24588, PubMed 24532410

Grinde MT, Skrbo N, Moestue SA, Rødland EA, Borgan E, Kristian A, Sitter B, Bathen TF, Børresen-Dale AL, Mælandsmo GM, Engebraaten O, Sørlie T, Marangoni E, Gribbestad IS (2014)
Interplay of choline metabolites and genes in patient-derived breast cancer xenografts
Breast Cancer Res, 16 (1), R5
DOI 10.1186/bcr3597, PubMed 24447408

Haugen MH, Boye K, Nesland JM, Pettersen SJ, Egeland EV, Tamhane T, Brix K, Maelandsmo GM, Flatmark K (2014)
High expression of the cysteine proteinase legumain in colorectal cancer - implications for therapeutic targeting
Eur J Cancer, 51 (1), 9-17
DOI 10.1016/j.ejca.2014.10.020, PubMed 25466510

Hidalgo M, Amant F, Biankin AV, Budinská E, Byrne AT, Caldas C, Clarke RB, de Jong S, Jonkers J, Mælandsmo GM, Roman-Roman S, Seoane J, Trusolino L, Villanueva A (2014)
Patient-derived xenograft models: an emerging platform for translational cancer research
Cancer Discov, 4 (9), 998-1013
DOI 10.1158/2159-8290.CD-14-0001, PubMed 25185190

Kristian A, Riss P, Qu H, Milde M, Schoultz BW, Engebraaten O, Mælandsmo GM, Malinen E (2014)
Positron emission tomography and pharmacokinetics of 2-[18F]-fluoroethyl choline for metabolic studies in breast cancer xenografts
Acta Oncol, 53 (8), 1086-92
DOI 10.3109/0284186X.2014.934398, PubMed 25017377

Momtazi L, Bagherifam S, Singh G, Hofgaard A, Hakkarainen M, Glomm WR, Roos N, Mælandsmo GM, Griffiths G, Nyström B (2014)
Synthesis, characterization, and cellular uptake of magnetic nanocarriers for cancer drug delivery
J Colloid Interface Sci, 433, 76-85
DOI 10.1016/j.jcis.2014.07.013, PubMed 25112915

Skrbo N, Hjortland GO, Kristian A, Holm R, Nord S, Prasmickaite L, Engebraaten O, Mælandsmo GM, Sørlie T, Andersen K (2014)
Differential in vivo tumorigenicity of distinct subpopulations from a luminal-like breast cancer xenograft
PLoS One, 9 (11), e113278
DOI 10.1371/journal.pone.0113278, PubMed 25419568

Publications 2013

Bettum IJ, Vasiliauskaite K, Nygaard V, Clancy T, Pettersen SJ, Tenstad E, Mælandsmo GM, Prasmickaite L (2013)
Metastasis-associated protein S100A4 induces a network of inflammatory cytokines that activate stromal cells to acquire pro-tumorigenic properties
Cancer Lett, 344 (1), 28-39
DOI 10.1016/j.canlet.2013.10.036, PubMed 24215866

Bruheim S, Sandvold ML, Mælandsmo GM, Fodstad O (2013)
Antitumor activity of elacytarabine combined with bevacizumab, cetuximab and trastuzumab in human NSCLC xenografts
Anticancer Res, 33 (9), 3615-21
PubMed 24023287

Esmaeili M, Bathen TF, Engebråten O, Mælandsmo GM, Gribbestad IS, Moestue SA (2013)
Quantitative (31)P HR-MAS MR spectroscopy for detection of response to PI3K/mTOR inhibition in breast cancer xenografts
Magn Reson Med, 71 (6), 1973-81
DOI 10.1002/mrm.24869, PubMed 23878023

Haugen MH, Johansen HT, Pettersen SJ, Solberg R, Brix K, Flatmark K, Maelandsmo GM (2013)
Nuclear legumain activity in colorectal cancer
PLoS One, 8 (1), e52980
DOI 10.1371/journal.pone.0052980, PubMed 23326369

Jin Y, Qu S, Tesikova M, Wang L, Kristian A, Mælandsmo GM, Kong H, Zhang T, Jerónimo C, Teixeira MR, Yuca E, Tekedereli I, Gorgulu K, Alpay N, Sood AK, Lopez-Berestein G, Danielsen HE, Ozpolat B, Saatcioglu F (2013)
Molecular circuit involving KLK4 integrates androgen and mTOR signaling in prostate cancer
Proc Natl Acad Sci U S A, 110 (28), E2572-81
DOI 10.1073/pnas.1304318110, PubMed 23798432

Kongsgaard A, Borgen E, Mælandsmo GM, Flatmark K, Le H, Josefsen D, Solvoll I, Schirmer CB, Helland Å, Jørgensen L, Brustugun OT, Fodstad Ø, Boye K (2013)
Clinical significance of disseminated tumour cells in non-small cell lung cancer
Br J Cancer, 109 (5), 1264-70
DOI 10.1038/bjc.2013.450, PubMed 23942067

Kongsgaard A, Boye K, Oijordsbakken M, Lund-Iversen M, Halvorsen AR, Solberg SK, Berge G, Helland A, Brustugun OT, Mælandsmo GM (2013)
Osteopontin is a prognostic biomarker in non-small cell lung cancer
BMC Cancer, 13, 540
DOI 10.1186/1471-2407-13-540, PubMed 24215488

Kristian A, Nilsen LB, Røe K, Revheim ME, Engebråten O, Mælandsmo GM, Holm R, Malinen E, Seierstad T (2013)
Dynamic (18) F-FDG PET for Assessment of Tumor Physiology in Two Breast Carcinoma Xenografts
Nucl Med Mol Imaging, 47 (3), 173-80
DOI 10.1007/s13139-013-0211-y, PubMed 24900104

Kristian A, Revheim ME, Qu H, Mælandsmo GM, Engebråten O, Seierstad T, Malinen E (2013)
Dynamic (18)F-FDG-PET for monitoring treatment effect following anti-angiogenic therapy in triple-negative breast cancer xenografts
Acta Oncol, 52 (7), 1566-72
DOI 10.3109/0284186X.2013.813634, PubMed 23984812

Lindholm EM, Krohn M, Iadevaia S, Kristian A, Mills GB, Mælandsmo GM, Engebraaten O (2013)
Proteomic characterization of breast cancer xenografts identifies early and late bevacizumab-induced responses and predicts effective drug combinations
Clin Cancer Res, 20 (2), 404-12
DOI 10.1158/1078-0432.CCR-13-1865, PubMed 24192926

Moestue SA, Dam CG, Gorad SS, Kristian A, Bofin A, Mælandsmo GM, Engebråten O, Gribbestad IS, Bjørkøy G (2013)
Metabolic biomarkers for response to PI3K inhibition in basal-like breast cancer
Breast Cancer Res, 15 (1), R16
DOI 10.1186/bcr3391, PubMed 23448424

Moestue SA, Huuse EM, Lindholm EM, Bofin A, Engebraaten O, Mælandsmo GM, Akslen LA, Gribbestad IS (2013)
Low-molecular contrast agent dynamic contrast-enhanced (DCE)-MRI and diffusion-weighted (DW)-MRI in early assessment of bevacizumab treatment in breast cancer xenografts
J Magn Reson Imaging, 38 (5), 1043-53
DOI 10.1002/jmri.24079, PubMed 23908122

Publications 2012

Borgan E, Lindholm EM, Moestue S, Mælandsmo GM, Lingjærde OC, Gribbestad IS, Børresen-Dale AL, Engebraaten O, Sørlie T (2012)
Subtype-specific response to bevacizumab is reflected in the metabolome and transcriptome of breast cancer xenografts
Mol Oncol, 7 (1), 130-42
DOI 10.1016/j.molonc.2012.10.005, PubMed 23142657

Boye K, Nesland JM, Sandstad B, Haugland Haugen M, Mælandsmo GM, Flatmark K (2012)
EMMPRIN is associated with S100A4 and predicts patient outcome in colorectal cancer
Br J Cancer, 107 (4), 667-74
DOI 10.1038/bjc.2012.293, PubMed 22782346

Engesæter B, Engebraaten O, Flørenes VA, Mælandsmo GM (2012)
Dacarbazine and the agonistic TRAIL receptor-2 antibody lexatumumab induce synergistic anticancer effects in melanoma
PLoS One, 7 (9), e45492
DOI 10.1371/journal.pone.0045492, PubMed 23029050

Kernstock S, Davydova E, Jakobsson M, Moen A, Pettersen S, Mælandsmo GM, Egge-Jacobsen W, Falnes PØ (2012)
Lysine methylation of VCP by a member of a novel human protein methyltransferase family
Nat Commun, 3, 1038
DOI 10.1038/ncomms2041, PubMed 22948820

Kongsgaard A, Lund-Iversen M, Berge G, Brustugun OT, Solberg SK, Mælandsmo GM, Boye K (2012)
Expression of S100A4, ephrin-A1 and osteopontin in non-small cell lung cancer
BMC Cancer, 12, 333
DOI 10.1186/1471-2407-12-333, PubMed 22853000

Lindholm EM, Kristian A, Nalwoga H, Krüger K, Nygård S, Akslen LA, Mælandsmo GM, Engebraaten O (2012)
Effect of antiangiogenic therapy on tumor growth, vasculature and kinase activity in basal- and luminal-like breast cancer xenografts
Mol Oncol, 6 (4), 418-27
DOI 10.1016/j.molonc.2012.03.006, PubMed 22521242

Selbo PK, Weyergang A, Eng MS, Bostad M, Mælandsmo GM, Høgset A, Berg K (2012)
Strongly amphiphilic photosensitizers are not substrates of the cancer stem cell marker ABCG2 and provides specific and efficient light-triggered drug delivery of an EGFR-targeted cytotoxic drug
J Control Release, 159 (2), 197-203
DOI 10.1016/j.jconrel.2012.02.003, PubMed 22349185

Slipicevic A, Holm R, Emilsen E, Ree Rosnes AK, Welch DR, Mælandsmo GM, Flørenes VA (2012)
Cytoplasmic BRMS1 expression in malignant melanoma is associated with increased disease-free survival
BMC Cancer, 12, 73
DOI 10.1186/1471-2407-12-73, PubMed 22356677

Slipicevic A, Øy GF, Rosnes AK, Stakkestad Ø, Emilsen E, Engesæter B, Mælandsmo GM, Flørenes VA (2012)
Low-dose anisomycin sensitizes melanoma cells to TRAIL induced apoptosis
Cancer Biol Ther, 14 (2), 146-54
DOI 10.4161/cbt.22953, PubMed 23192275

Smith R, Johansen HT, Nilsen H, Haugen MH, Pettersen SJ, Mælandsmo GM, Abrahamson M, Solberg R (2012)
Intra- and extracellular regulation of activity and processing of legumain by cystatin E/M
Biochimie, 94 (12), 2590-9
DOI 10.1016/j.biochi.2012.07.026, PubMed 22902879

Publications 2011

Berge G, Pettersen S, Grotterød I, Bettum IJ, Boye K, Mælandsmo GM (2011)
Osteopontin--an important downstream effector of S100A4-mediated invasion and metastasis
Int J Cancer, 129 (4), 780-90
DOI 10.1002/ijc.25735, PubMed 20957651

Engesæter BO, Sathermugathevan M, Hellenes T, Engebråten O, Holm R, Flørenes VA, Mælandsmo GM (2011)
Targeting inhibitor of apoptosis proteins in combination with dacarbazine or TRAIL in melanoma cells
Cancer Biol Ther, 12 (1), 47-58
DOI 10.4161/cbt.12.1.15714, PubMed 21508672

Huuse EM, Moestue SA, Lindholm EM, Bathen TF, Nalwoga H, Krüger K, Bofin A, Maelandsmo GM, Akslen LA, Engebraaten O, Gribbestad IS (2011)
In vivo MRI and histopathological assessment of tumor microenvironment in luminal-like and basal-like breast cancer xenografts
J Magn Reson Imaging, 35 (5), 1098-107
DOI 10.1002/jmri.23507, PubMed 22170753

Liu H, Tekle C, Chen YW, Kristian A, Zhao Y, Zhou M, Liu Z, Ding Y, Wang B, Mælandsmo GM, Nesland JM, Fodstad O, Tan M (2011)
B7-H3 silencing increases paclitaxel sensitivity by abrogating Jak2/Stat3 phosphorylation
Mol Cancer Ther, 10 (6), 960-71
DOI 10.1158/1535-7163.MCT-11-0072, PubMed 21518725

Tekle C, Nygren MK, Chen YW, Dybsjord I, Nesland JM, Maelandsmo GM, Fodstad O (2011)
B7-H3 contributes to the metastatic capacity of melanoma cells by modulation of known metastasis-associated genes
Int J Cancer, 130 (10), 2282-90
DOI 10.1002/ijc.26238, PubMed 21671471

Publications 2010

Andersen K, Mori H, Fata J, Bascom J, Oyjord T, Mælandsmo GM, Bissell M (2010)
The metastasis-promoting protein S100A4 regulates mammary branching morphogenesis
Dev Biol, 352 (2), 181-90
DOI 10.1016/j.ydbio.2010.12.033, PubMed 21195708

Berge G, Andersen K, Haugen MH, Maelandsmo GM (2010)
Comment on the Importance of S100A4 in regulation of MMP-13
J Biol Chem, 285 (53), le23; author reply le24
DOI 10.1074/jbc.L110.125898, PubMed 21186294

Berge G, Costea DE, Berg M, Rasmussen H, Grotterød I, Lothe RA, Mælandsmo GM, Flatmark K (2010)
Coexpression and nuclear colocalization of metastasis-promoting protein S100A4 and p53 without mutual regulation in colorectal carcinoma
Amino Acids, 41 (4), 875-84
DOI 10.1007/s00726-010-0514-6, PubMed 20191297

Berge G, Mælandsmo GM (2010)
Evaluation of potential interactions between the metastasis-associated protein S100A4 and the tumor suppressor protein p53
Amino Acids, 41 (4), 863-73
DOI 10.1007/s00726-010-0497-3, PubMed 20177948

Boye K, Nesland JM, Sandstad B, Mælandsmo GM, Flatmark K (2010)
Nuclear S100A4 is a novel prognostic marker in colorectal cancer
Eur J Cancer, 46 (16), 2919-25
DOI 10.1016/j.ejca.2010.07.013, PubMed 20719498

Briggs JJ, Haugen MH, Johansen HT, Riker AI, Abrahamson M, Fodstad Ø, Maelandsmo GM, Solberg R (2010)
Cystatin E/M suppresses legumain activity and invasion of human melanoma
BMC Cancer, 10, 17
DOI 10.1186/1471-2407-10-17, PubMed 20074384

Grotterød I, Maelandsmo GM, Boye K (2010)
Signal transduction mechanisms involved in S100A4-induced activation of the transcription factor NF-kappaB
BMC Cancer, 10, 241
DOI 10.1186/1471-2407-10-241, PubMed 20507646

Kaarbø M, Mikkelsen OL, Malerød L, Qu S, Lobert VH, Akgul G, Halvorsen T, Maelandsmo GM, Saatcioglu F (2010)
PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells
Cell Oncol, 32 (1-2), 11-27
DOI 10.3233/CLO-2009-0487, PubMed 20203370

Moestue SA, Borgan E, Huuse EM, Lindholm EM, Sitter B, Børresen-Dale AL, Engebraaten O, Maelandsmo GM, Gribbestad IS (2010)
Distinct choline metabolic profiles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft models
BMC Cancer, 10, 433
DOI 10.1186/1471-2407-10-433, PubMed 20716336

Oy GF, Slipicevic A, Davidson B, Solberg Faye R, Maelandsmo GM, Flørenes VA (2010)
Biological effects induced by insulin-like growth factor binding protein 3 (IGFBP-3) in malignant melanoma
Int J Cancer, 126 (2), 350-61
DOI 10.1002/ijc.24727, PubMed 19588500

Paus E, Haugen MH, Olsen KH, Flatmark K, Maelandsmo GM, Nilsson O, Röijer E, Lundin M, Fermér C, Samsonova M, Lebedin Y, Stigbrand T (2010)
TD-11 workshop report: characterization of monoclonal antibodies to S100 proteins
Tumour Biol, 32 (1), 1-12
DOI 10.1007/s13277-010-0073-1, PubMed 20652782

Prasmickaite L, Engesaeter BØ, Skrbo N, Hellenes T, Kristian A, Oliver NK, Suo Z, Maelandsmo GM (2010)
Aldehyde dehydrogenase (ALDH) activity does not select for cells with enhanced aggressive properties in malignant melanoma
PLoS One, 5 (5), e10731
DOI 10.1371/journal.pone.0010731, PubMed 20505780

Prasmickaite L, Skrbo N, Høifødt HK, Suo Z, Engebråten O, Gullestad HP, Aamdal S, Fodstad Ø, Maelandsmo GM (2010)
Human malignant melanoma harbours a large fraction of highly clonogenic cells that do not express markers associated with cancer stem cells
Pigment Cell Melanoma Res, 23 (3), 449-51
DOI 10.1111/j.1755-148X.2010.00690.x, PubMed 20236249

Røe K, Seierstad T, Kristian A, Mikalsen LT, Mælandsmo GM, van der Kogel AJ, Ree AH, Olsen DR (2010)
Longitudinal magnetic resonance imaging-based assessment of vascular changes and radiation response in androgen-sensitive prostate carcinoma xenografts under androgen-exposed and androgen-deprived conditions
Neoplasia, 12 (10), 818-25
DOI 10.1593/neo.10484, PubMed 20927320

Wang L, Jin Y, Arnoldussen YJ, Jonson I, Qu S, Maelandsmo GM, Kristian A, Risberg B, Waehre H, Danielsen HE, Saatcioglu F (2010)
STAMP1 is both a proliferative and an antiapoptotic factor in prostate cancer
Cancer Res, 70 (14), 5818-28
DOI 10.1158/0008-5472.CAN-09-4697, PubMed 20587517

Wiiger MT, Gehrken HB, Fodstad Ø, Maelandsmo GM, Andersson Y (2010)
A novel human recombinant single-chain antibody targeting CD166/ALCAM inhibits cancer cell invasion in vitro and in vivo tumour growth
Cancer Immunol Immunother, 59 (11), 1665-74
DOI 10.1007/s00262-010-0892-3, PubMed 20635083

Publications 2009

Bergamaschi A, Hjortland GO, Triulzi T, Sørlie T, Johnsen H, Ree AH, Russnes HG, Tronnes S, Maelandsmo GM, Fodstad O, Borresen-Dale AL, Engebraaten O (2009)
Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models
Mol Oncol, 3 (5-6), 469-82
DOI 10.1016/j.molonc.2009.07.003, PubMed 19713161

Boye K, Maelandsmo GM (2009)
S100A4 and metastasis: a small actor playing many roles
Am J Pathol, 176 (2), 528-35
DOI 10.2353/ajpath.2010.090526, PubMed 20019188

Cedervall J, Jamil S, Prasmickaite L, Cheng Y, Eskandarpour M, Hansson J, Maelandsmo GM, Ringborg U, Gulyas M, Zhen HS, Kanter L, Ahrlund-Richter L (2009)
Species-specific in vivo engraftment of the human BL melanoma cell line results in an invasive dedifferentiated phenotype not present in xenografts
Cancer Res, 69 (9), 3746-54
DOI 10.1158/0008-5472.CAN-08-3746, PubMed 19383913

Elenjord R, Allen JB, Johansen HT, Kildalsen H, Svineng G, Maelandsmo GM, Loennechen T, Winberg JO (2009)
Collagen I regulates matrix metalloproteinase-2 activation in osteosarcoma cells independent of S100A4
FEBS J, 276 (18), 5275-86
DOI 10.1111/j.1742-4658.2009.07223.x, PubMed 19682073

Hoyem S, Bruheim S, Maelandsmo G, Standal M, Olberg DE, Brudeli B, Asberg A, Klaveness J, Rongved P (2009)
Didanosine ester prodrugs: Synthesis, albumin binding properties and pharmacokinetic studies in rats (vol 44, pg 3874, 2009)
Eur. J. Med. Chem., 44 (11), 4786
DOI 10.1016/j.ejmech.2009.08.006

Høyem S, Bruheim S, Maelandsmo G, Olberg DE, Brudeli B, Asberg A, Klaveness J, Rongved P (2009)
Didanosine ester prodrugs: synthesis, albumin binding properties and pharmacokinetic studies in rats
Eur J Med Chem, 44 (10), 3874-9
DOI 10.1016/j.ejmech.2009.04.008, PubMed 19433342

Maelandsmo GM, Flørenes VA, Nguyen MT, Flatmark K, Davidson B (2009)
Different expression and clinical role of S100A4 in serous ovarian carcinoma at different anatomic sites
Tumour Biol, 30 (1), 15-25
DOI 10.1159/000199447, PubMed 19194111

Publications 2008

Arnoldussen YJ, Lorenzo PI, Pretorius ME, Waehre H, Risberg B, Maelandsmo GM, Danielsen HE, Saatcioglu F (2008)
The mitogen-activated protein kinase phosphatase vaccinia H1-related protein inhibits apoptosis in prostate cancer cells and is overexpressed in prostate cancer
Cancer Res, 68 (22), 9255-64
DOI 10.1158/0008-5472.CAN-08-1224, PubMed 19010898

Boye K, Grotterød I, Aasheim HC, Hovig E, Maelandsmo GM (2008)
Activation of NF-kappaB by extracellular S100A4: analysis of signal transduction mechanisms and identification of target genes
Int J Cancer, 123 (6), 1301-10
DOI 10.1002/ijc.23617, PubMed 18548584

Faye RS, Paus E, Maelandsmo GM, Berner A, Høifødt HK, Fodstad Ø, Aamdal S (2008)
S100B in bone marrow aspirates in healthy individuals and malignant melanoma patients
Melanoma Res, 18 (2), 134-40
DOI 10.1097/CMR.0b013e3282f623d9, PubMed 18337650

Haugen MH, Flatmark K, Mikalsen SO, Malandsmo GM (2008)
The metastasis-associated protein S100A4 exists in several charged variants suggesting the presence of posttranslational modifications
BMC Cancer, 8, 172
DOI 10.1186/1471-2407-8-172, PubMed 18554396

Publications 2007

Berg K, Folini M, Prasmickaite L, Selbo PK, Bonsted A, Engesaeter BØ, Zaffaroni N, Weyergang A, Dietze A, Maelandsmo GM, Wagner E, Norum OJ, Høgset A (2007)
Photochemical internalization: a new tool for drug delivery
Curr Pharm Biotechnol, 8 (6), 362-72
DOI 10.2174/138920107783018354, PubMed 18289045

Cabezón T, Celis JE, Skibshøj I, Klingelhöfer J, Grigorian M, Gromov P, Rank F, Myklebust JH, Maelandsmo GM, Lukanidin E, Ambartsumian N (2007)
Expression of S100A4 by a variety of cell types present in the tumor microenvironment of human breast cancer
Int J Cancer, 121 (7), 1433-44
DOI 10.1002/ijc.22850, PubMed 17565747

Lillehammer T, Engesaeter BO, Prasmickaite L, Maelandsmo GM, Fodstad O, Engebraaten O (2007)
Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell lines
J Gene Med, 9 (6), 440-51
DOI 10.1002/jgm.1036, PubMed 17410615

Rafferty M, Faller WJ, Moss C, McCormack J, Mãlandsmo GM, Easty DJ, Gallagher WM (2007)
Real-time quantitative reverse transcriptase-polymerase chain reaction analysis of melanoma progression-associated genes
Anticancer Res, 27 (3A), 1301-7
PubMed 17593623

Tveito S, Maelandsmo GM, Hoifodt HK, Rasmussen H, Fodstad O (2007)
Specific isolation of disseminated cancer cells: a new method permitting sensitive detection of target molecules of diagnostic and therapeutic value
Clin Exp Metastasis, 24 (5), 317-27
DOI 10.1007/s10585-006-9052-8, PubMed 17530423

Publications 2006

Bonsted A, Engesaeter BØ, Høgset A, Maelandsmo GM, Prasmickaite L, D'Oliveira C, Hennink WE, van Steenis JH, Berg K (2006)
Photochemically enhanced transduction of polymer-complexed adenovirus targeted to the epidermal growth factor receptor
J Gene Med, 8 (3), 286-97
DOI 10.1002/jgm.853, PubMed 16342300

Boye K, Andersen K, Tveito S, Øyjord T, Maelandsmo GM (2006)
Interferon-gamma-induced suppression of S100A4 transcription is mediated by the class II transactivator
Tumour Biol, 28 (1), 27-35
DOI 10.1159/000097700, PubMed 17143014

Engesaeter BØ, Bonsted A, Lillehammer T, Engebraaten O, Berg K, Maelandsmo GM (2006)
Photochemically mediated delivery of AdhCMV-TRAIL augments the TRAIL-induced apoptosis in colorectal cancer cell lines
Cancer Biol Ther, 5 (11), 1511-20
DOI 10.4161/cbt.5.11.3301, PubMed 17012835

Engesaeter BØ, Tveito S, Bonsted A, Engebraaten O, Berg K, Maelandsmo GM (2006)
Photochemical treatment with endosomally localized photosensitizers enhances the number of adenoviruses in the nucleus
J Gene Med, 8 (6), 707-18
DOI 10.1002/jgm.902, PubMed 16518880

Publications 2005

Bjørnland K, Flatmark K, Pettersen S, Aaasen AO, Fodstad O, Maelandsmo GM (2005)
Matrix metalloproteinases participate in osteosarcoma invasion
J Surg Res, 127 (2), 151-6
DOI 10.1016/j.jss.2004.12.016, PubMed 16083752

Engesaeter BØ, Bonsted A, Berg K, Høgset A, Engebråten O, Fodstad Ø, Curiel DT, Maelandsmo GM (2005)
PCI-enhanced adenoviral transduction employs the known uptake mechanism of adenoviral particles
Cancer Gene Ther, 12 (5), 439-48
DOI 10.1038/sj.cgt.7700808, PubMed 15678152

Lillehammer T, Tveito S, Engesaeter BO, Fodstad O, Maelandsmo GM, Engebraaten O (2005)
Melanoma-specific expression in first-generation adenoviral vectors in vitro and in vivo -- use of the human tyrosinase promoter with human enhancers
Cancer Gene Ther, 12 (11), 864-72
DOI 10.1038/sj.cgt.7700852, PubMed 15891771

Maelandsmo GM, Ross PJ, Pavliv M, Meulenbroek RA, Evelegh C, Muruve DA, Graham FL, Parks RJ (2005)
Use of a murine secreted alkaline phosphatase as a non-immunogenic reporter gene in mice
J Gene Med, 7 (3), 307-15
DOI 10.1002/jgm.666, PubMed 15515146

McArdle L, Rafferty MM, Satyamoorthy K, Maelandsmo GM, Dervan PA, Herlyn M, Easty DJ (2005)
Microarray analysis of phosphatase gene expression in human melanoma
Br J Dermatol, 152 (5), 925-30
DOI 10.1111/j.1365-2133.2005.06454.x, PubMed 15888148

Publications 2004

Andersen K, Nesland JM, Holm R, Flørenes VA, Fodstad Ø, Maelandsmo GM (2004)
Expression of S100A4 combined with reduced E-cadherin expression predicts patient outcome in malignant melanoma
Mod Pathol, 17 (8), 990-7
DOI 10.1038/modpathol.3800151, PubMed 15133476

Bonsted A, Engesaeter BØ, Høgset A, Maelandsmo GM, Prasmickaite L, Kaalhus O, Berg K (2004)
Transgene expression is increased by photochemically mediated transduction of polycation-complexed adenoviruses
Gene Ther, 11 (2), 152-60
DOI 10.1038/sj.gt.3302166, PubMed 14712299

Bruheim S, Bruland OS, Breistol K, Maelandsmo GM, Fodstad O (2004)
Human osteosarcoma xenografts and their sensitivity to chemotherapy
Pathol Oncol Res, 10 (3), 133-41
DOI 10.1007/BF03033741, PubMed 15448748

Flatmark K, Maelandsmo GM, Martinsen M, Rasmussen H, Fodstad Ø (2004)
Twelve colorectal cancer cell lines exhibit highly variable growth and metastatic capacities in an orthotopic model in nude mice
Eur J Cancer, 40 (10), 1593-8
DOI 10.1016/j.ejca.2004.02.023, PubMed 15196545

Flatmark K, Maelandsmo GM, Mikalsen SO, Nustad K, Varaas T, Rasmussen H, Meling GI, Fodstad Ø, Paus E (2004)
Immunofluorometric assay for the metastasis-related protein S100A4: release of S100A4 from normal blood cells prohibits the use of S100A4 as a tumor marker in plasma and serum
Tumour Biol, 25 (1-2), 31-40
DOI 10.1159/000077721, PubMed 15192310

Flørenes VA, Maelandsmo GM, Holm R, Reich R, Lazarovici P, Davidson B (2004)
Expression of activated TrkA protein in melanocytic tumors: relationship to cell proliferation and clinical outcome
Am J Clin Pathol, 122 (3), 412-20
DOI 10.1309/CHFH-EYAT-44WW-P7J3, PubMed 15362372

Muruve DA, Cotter MJ, Zaiss AK, White LR, Liu Q, Chan T, Clark SA, Ross PJ, Meulenbroek RA, Maelandsmo GM, Parks RJ (2004)
Helper-dependent adenovirus vectors elicit intact innate but attenuated adaptive host immune responses in vivo
J Virol, 78 (11), 5966-72
DOI 10.1128/JVI.78.11.5966-5972.2004, PubMed 15140994

Pedersen KB, Andersen K, Fodstad Ø, Maelandsmo GM (2004)
Sensitization of interferon-gamma induced apoptosis in human osteosarcoma cells by extracellular S100A4
BMC Cancer, 4, 52
DOI 10.1186/1471-2407-4-52, PubMed 15318945

Publications 2003

Andersen K, Smith-Sørensen B, Pedersen KB, Hovig E, Myklebost O, Fodstad Ø, Maelandsmo GM (2003)
Interferon-gamma suppresses S100A4 transcription independently of apoptosis or cell cycle arrest
Br J Cancer, 88 (12), 1995-2001
DOI 10.1038/sj.bjc.6600998, PubMed 12799648

Bratland A, Ragnhildstveit E, Bjørnland K, Andersen K, Maelandsmo GM, Fodstad O, Saatcioglu F, Ree AH (2003)
The metalloproteinase inhibitor TIMP-2 is down-regulated by androgens in LNCaP prostate carcinoma cells
Clin Exp Metastasis, 20 (6), 541-7
DOI 10.1023/a:1025860214891, PubMed 14598888

Flatmark K, Pedersen KB, Nesland JM, Rasmussen H, Aamodt G, Mikalsen SO, Bjørnland K, Fodstad Ø, Maelandsmo GM (2003)
Nuclear localization of the metastasis-related protein S100A4 correlates with tumour stage in colorectal cancer
J Pathol, 200 (5), 589-95
DOI 10.1002/path.1381, PubMed 12898594

Henriksen J, Aagesen TH, Maelandsmo GM, Lothe RA, Myklebost O, Forus A (2003)
Amplification and overexpression of COPS3 in osteosarcomas potentially target TP53 for proteasome-mediated degradation
Oncogene, 22 (34), 5358-61
DOI 10.1038/sj.onc.1206671, PubMed 12917637

Høgset A, Prasmickaite L, Engesaeter BO, Hellum M, Selbo PK, Olsen VM, Maelandsmo GM, Berg K (2003)
Light directed gene transfer by photochemical internalisation
Curr Gene Ther, 3 (2), 89-112
DOI 10.2174/1566523034578438, PubMed 12653404

Jørgensen K, Holm R, Maelandsmo GM, Flørenes VA (2003)
Expression of activated extracellular signal-regulated kinases 1/2 in malignant melanomas: relationship with clinical outcome
Clin Cancer Res, 9 (14), 5325-31
PubMed 14614017

Loennechen T, Mathisen B, Hansen J, Lindstad RI, El-Gewely SA, Andersen K, Maelandsmo GM, Winberg JO (2003)
Colchicine induces membrane-associated activation of matrix metalloproteinase-2 in osteosarcoma cells in an S100A4-independent manner
Biochem Pharmacol, 66 (12), 2341-53
DOI 10.1016/j.bcp.2003.08.014, PubMed 14637192

Maelandsmo GM, Holm R, Nesland JM, Fodstad Ø, Flørenes VA (2003)
Reduced beta-catenin expression in the cytoplasm of advanced-stage superficial spreading malignant melanoma
Clin Cancer Res, 9 (9), 3383-8
PubMed 12960126

Mathisen B, Lindstad RI, Hansen J, El-Gewely SA, Maelandsmo GM, Hovig E, Fodstad O, Loennechen T, Winberg JO (2003)
S100A4 regulates membrane induced activation of matrix metalloproteinase-2 in osteosarcoma cells
Clin Exp Metastasis, 20 (8), 701-11
DOI 10.1023/b:clin.0000006819.21361.03, PubMed 14713104

Publications 2002

Høgset A, Engesaeter BO, Prasmickaite L, Berg K, Fodstad O, Maelandsmo GM (2002)
Light-induced adenovirus gene transfer, an efficient and specific gene delivery technology for cancer gene therapy
Cancer Gene Ther, 9 (4), 365-71
DOI 10.1038/sj.cgt.7700447, PubMed 11960287

Meza-Zepeda LA, Forus A, Lygren B, Dahlberg AB, Godager LH, South AP, Marenholz I, Lioumi M, Flørenes VA, Maelandsmo GM, Serra M, Mischke D, Nizetic D, Ragoussis J, Tarkkanen M, Nesland JM, Knuutila S, Myklebost O (2002)
Positional cloning identifies a novel cyclophilin as a candidate amplified oncogene in 1q21
Oncogene, 21 (14), 2261-9
DOI 10.1038/sj.onc.1205339, PubMed 11948409

Pedersen KB, Nesland JM, Fodstad Ø, Maelandsmo GM (2002)
Expression of S100A4, E-cadherin, alpha- and beta-catenin in breast cancer biopsies
Br J Cancer, 87 (11), 1281-6
DOI 10.1038/sj.bjc.6600624, PubMed 12439718

Ree AH, Bratland A, Kroes RA, Aasheim HC, Flørenes VA, Moskal JR, Fodstad O, Bruland OS, Maelandsmo GM (2002)
Clinical and cell line specific expression profiles of a human gene identified in experimental central nervous system metastases
Anticancer Res, 22 (4), 1949-57
PubMed 12174869

Publications 2001

Bjørnland K, Bratland A, Rugnes E, Pettersen S, Johansen HT, Aasen AO, Fodstad Ø, Ree AH, Maelandsmo GM (2001)
Expression of matrix metalloproteinases and the metastasis-associated gene S100A4 in human neuroblastoma and primitive neuroectodermal tumor cells
J Pediatr Surg, 36 (7), 1040-4
DOI 10.1053/jpsu.2001.24735, PubMed 11431772

Flørenes VA, Maelandsmo GM, Faye R, Nesland JM, Holm R (2001)
Cyclin A expression in superficial spreading malignant melanomas correlates with clinical outcome
J Pathol, 195 (5), 530-6
DOI 10.1002/path.1007, PubMed 11745687

Forus A, D'Angelo A, Henriksen J, Merla G, Maelandsmo GM, Flørenes VA, Olivieri S, Bjerkehagen B, Meza-Zepeda LA, del Vecchio Blanco F, Müller C, Sanvito F, Kononen J, Nesland JM, Fodstad Ø, Reymond A, Kallioniemi OP, Arrigoni G, Ballabio A, Myklebost O, Zollo M (2001)
Amplification and overexpression of PRUNE in human sarcomas and breast carcinomas-a possible mechanism for altering the nm23-H1 activity
Oncogene, 20 (47), 6881-90
DOI 10.1038/sj.onc.1204874, PubMed 11687967

Hovig E, Maelandsmo G, Mellingsaeter T, Fodstad O, Mielewczyk SS, Wolfe J, Goodchild J (2001)
Optimization of hammerhead ribozymes for the cleavage of S100A4 (CAPL) mRNA
Antisense Nucleic Acid Drug Dev, 11 (2), 67-75
DOI 10.1089/108729001750171272, PubMed 11334142

McArdle L, Rafferty M, Maelandsmo GM, Bergin O, Farr CJ, Dervan PA, O'Loughlin S, Herlyn M, Easty DJ (2001)
Protein tyrosine phosphatase genes downregulated in melanoma
J Invest Dermatol, 117 (5), 1255-60
DOI 10.1046/j.0022-202x.2001.01534.x, PubMed 11710941

Publications 2000

Bratland A, Risberg K, Maelandsmo GM, Gützkow KB, Olsen OE, Moghaddam A, Wang MY, Hansen CM, Blomhoff HK, Berg JP, Fodstad O, Ree AH (2000)
Expression of a novel factor, com1, is regulated by 1,25-dihydroxyvitamin D3 in breast cancer cells
Cancer Res, 60 (19), 5578-83
PubMed 11034106

Flørenes VA, Faye RS, Maelandsmo GM, Nesland JM, Holm R (2000)
Levels of cyclin D1 and D3 in malignant melanoma: deregulated cyclin D3 expression is associated with poor clinical outcome in superficial melanoma
Clin Cancer Res, 6 (9), 3614-20
PubMed 10999753

Fosså A, Siebert R, Aasheim HC, Maelandsmo GM, Berner A, Fosså SD, Paus E, Smeland EB, Gaudernack G (2000)
Identification of nucleolar protein No55 as a tumour-associated autoantigen in patients with prostate cancer
Br J Cancer, 83 (6), 743-9
DOI 10.1054/bjoc.2000.1365, PubMed 10952778

Publications 1999

Bjørnland K, Winberg JO, Odegaard OT, Hovig E, Loennechen T, Aasen AO, Fodstad O, Maelandsmo GM (1999)
S100A4 involvement in metastasis: deregulation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in osteosarcoma cells transfected with an anti-S100A4 ribozyme
Cancer Res, 59 (18), 4702-8
PubMed 10493528

Publications 1998

Andersen K, Maelandsmo GM, Hovig E, Fodstad O, Loennechen T, Winberg JO (1998)
Interleukin-1 alpha and basic fibroblast growth factor induction of matrix metalloproteinases and their inhibitors in osteosarcoma cells is modulated by the metastasis associated protein CAPL
Anticancer Res, 18 (5A), 3299-303
PubMed 9858899

Flørenes VA, Maelandsmo GM, Kerbel RS, Slingerland JM, Nesland JM, Holm R (1998)
Protein expression of the cell-cycle inhibitor p27Kip1 in malignant melanoma: inverse correlation with disease-free survival
Am J Pathol, 153 (1), 305-12
DOI 10.1016/S0002-9440(10)65572-1, PubMed 9665492

Hjelstuen OK, Maelandsmo GM, Tønnesen HH, Bremmer PO, Verbruggen AM (1998)
Hybridization of a 99Tcm-labelled oligodeoxynucleotide to CAPL RNA
Nucl Med Commun, 19 (8), 803-12
DOI 10.1097/00006231-199808000-00012, PubMed 9751936

Prasmickaite L, Hogset A, Maelandsmo G, Berg K, Goodchild J, Perkins T, Fodstad O, Hovig E (1998)
Intracellular metabolism of a 2'-O-methyl-stabilized ribozyme after uptake by DOTAP transfection or asfree ribozyme. A study by capillary electrophoresis
Nucleic Acids Res, 26 (18), 4241-8
DOI 10.1093/nar/26.18.4241, PubMed 9722645

Publications 1997

de Graaf H, Maelandsmo GM, Ruud P, Forus A, Oyjord T, Fodstad O, Hovig E (1997)
Ectopic expression of target genes may represent an inherent limitation of RT-PCR assays used for micrometastasis detection: studies on the epithelial glycoprotein gene EGP-2
Int J Cancer, 72 (1), 191-6
DOI 10.1002/(sici)1097-0215(19970703)72:1<191::aid-ijc27>3.0.co;2-l, PubMed 9212242

Maelandsmo GM, Flørenes VA, Mellingsaeter T, Hovig E, Kerbel RS, Fodstad O (1997)
Differential expression patterns of S100A2, S100A4 and S100A6 during progression of human malignant melanoma
Int J Cancer, 74 (4), 464-9
DOI 10.1002/(sici)1097-0215(19970822)74:4<464::aid-ijc19>3.0.co;2-9, PubMed 9291441

Ree AH, Florenes VA, Berg JP, Maelandsmo GM, Nesland JM, Fodstad O (1997)
High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases
Clin Cancer Res, 3 (9), 1623-8
PubMed 9815852

Publications 1996

Maelandsmo GM, Flørenes VA, Hovig E, Oyjord T, Engebraaten O, Holm R, Børresen AL, Fodstad O (1996)
Involvement of the pRb/p16/cdk4/cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas
Br J Cancer, 73 (8), 909-16
DOI 10.1038/bjc.1996.181, PubMed 8611425

Maelandsmo GM, Holm R, Fodstad O, Kerbel RS, Flørenes VA (1996)
Cyclin kinase inhibitor p21WAF1/CIP1 in malignant melanoma: reduced expression in metastatic lesions
Am J Pathol, 149 (6), 1813-22
PubMed 8952518

Maelandsmo GM, Hovig E, Skrede M, Engebraaten O, Flørenes VA, Myklebost O, Grigorian M, Lukanidin E, Scanlon KJ, Fodstad O (1996)
Reversal of the in vivo metastatic phenotype of human tumor cells by an anti-CAPL (mts1) ribozyme
Cancer Res, 56 (23), 5490-8
PubMed 8968106

Ree AH, Maelandsmo GM, Fodstad O (1996)
Regulation of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in MCF-7 cells: comparison with regulatory mechanisms of pS2 expression
Clin Exp Metastasis, 14 (4), 381-8
DOI 10.1007/BF00123397, PubMed 8878412

Publications 1995

Maelandsmo GM, Berner JM, Flørenes VA, Forus A, Hovig E, Fodstad O, Myklebost O (1995)
Homozygous deletion frequency and expression levels of the CDKN2 gene in human sarcomas--relationship to amplification and mRNA levels of CDK4 and CCND1
Br J Cancer, 72 (2), 393-8
DOI 10.1038/bjc.1995.344, PubMed 7640224

Publications 1994

Flørenes VA, Maelandsmo GM, Forus A, Andreassen A, Myklebost O, Fodstad O (1994)
MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status
J Natl Cancer Inst, 86 (17), 1297-302
DOI 10.1093/jnci/86.17.1297, PubMed 8064888

Forus A, Flørenes VA, Maelandsmo GM, Fodstad O, Myklebost O (1994)
The protooncogene CHOP/GADD153, involved in growth arrest and DNA damage response, is amplified in a subset of human sarcomas
Cancer Genet Cytogenet, 78 (2), 165-71
DOI 10.1016/0165-4608(94)90085-x, PubMed 7828148

Publications 1993

Forus A, Flørenes VA, Maelandsmo GM, Meltzer PS, Fodstad O, Myklebost O (1993)
Mapping of amplification units in the q13-14 region of chromosome 12 in human sarcomas: some amplica do not include MDM2
Cell Growth Differ, 4 (12), 1065-70
PubMed 8117620

Publications 1992

Flørenes VA, Aamdal S, Myklebost O, Maelandsmo GM, Bruland OS, Fodstad O (1992)
Levels of nm23 messenger RNA in metastatic malignant melanomas: inverse correlation to disease progression
Cancer Res, 52 (21), 6088-91
PubMed 1356624

Nenseter MS, Gudmundsen O, Roos N, Maelandsmo G, Drevon CA, Berg T (1992)
Role of liver endothelial and Kupffer cells in clearing low density lipoprotein from blood in hypercholesterolemic rabbits
J Lipid Res, 33 (6), 867-77
PubMed 1324967

Nenseter MS, Rustan AC, Lund-Katz S, Søyland E, Maelandsmo G, Phillips MC, Drevon CA (1992)
Effect of dietary supplementation with n-3 polyunsaturated fatty acids on physical properties and metabolism of low density lipoprotein in humans
Arterioscler Thromb, 12 (3), 369-79
DOI 10.1161/01.atv.12.3.369, PubMed 1532127

Skrede B, Blomhoff R, Maelandsmo GM, Ose L, Myklebost O, Norum KR (1992)
Uptake of chylomicron remnant retinyl esters in human leukocytes in vivo
Eur J Clin Invest, 22 (4), 229-34
DOI 10.1111/j.1365-2362.1992.tb01456.x, PubMed 1499639

Publications 1989

Maelandsmo GM, Ostvold AC, Laland SG (1989)
Phosphorylation of the high-mobility-group-like protein P1 by casein kinase-2
Eur J Biochem, 184 (3), 529-34
DOI 10.1111/j.1432-1033.1989.tb15046.x, PubMed 2806236